INVA Stock Analysis: Buy, Sell, or Hold?
INVA - Innoviva, Inc. Common Stock
$22.31
0.41 (1.87%)
▲
5d:
-4.45%
30d:
+4.5%
90d:
-4.7%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When INVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: INVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.63
Based on 9.9% avg growth
INTRINSIC VALUE TODAY
$22.75
1.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INVA is currently trading at $22.31, which is considered extended relative to its 30-day fair value range of $21.81 to $23.03. The stock's valuation (Forward PE: 10.1) is in line with its historical norms (10.4). Remarkably, the market is currently pricing in an annual earnings decline of 1.0% over the next few years. This pessimistic expectation contrasts with the company's recent 590.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INVA is showing sideways momentum. The price is currently testing key support at $21.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.50 (+59.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INVA is showing sideways momentum. The price is currently testing key support at $21.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.50 (+59.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$21.81 -
$23.03
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.0%
Protect Your Profits
Holding INVA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.1% below Wall St target ($35.50)
Trading Range Analysis
30-Day Trading Range
$21.81 -
$23.03
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$21.70
Resistance Level
$24.17
Current Trend
Sideways
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.10
Wall Street Target
$35.50
(+59.1%)
Revenue Growth (YoY)
10.6%
Earnings Growth (YoY)
590.4%
Profit Margin
119.9%
Valuation Discount vs History
-1.0% cheaper
PE vs Historical
10.1 vs 10.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.0%
(market-implied from PE analysis)
1-Year Target
$22.09
(-1%)
2-Year Target
$21.87
(-2%)
3-Year Target
$21.65
(-3%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
$22.30
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 15.7%)
$74.56
(+234%)
Base:
(SPY PE: 10.1, Growth: 15.7%)
$34.56
(+55%)
Bear:
(PE: 8.6, Growth: 15.7%)
$29.38
(+32%)
📈
Valuation based on Current Earnings
Trailing PE: 3.50 | Current EPS (TTM): $6.26
Bull Case
$12.04
(-46%)
Analyst growth -50.0%, PE expands to 3.9
Base Case
$10.95
(-51%)
Market implied -50.0%, PE stable at 3.5
Bear Case
$14.89
(-33%)
Severe decline -20.0%, PE contracts to 3.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.1 to 10.4
Stabilization Target:
$22.98
(+3.0%)
PE Expansion Potential:
+3.0%
Share & Embed Analysis
Last updated: July 03, 2026 8:10 PM ET
Data refreshes hourly during market hours. Next update: 9:10 PM
Data refreshes hourly during market hours. Next update: 9:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
Advanced INVA Option Strategies
Professional options setups generated by AI based on today's INVA price and gamma walls.
